undamentalytics Newsletter
Sign in

Axsome Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Axsome Therapeutics, Inc. had total assets of $690m, total liabilities of $602m and shareholders' equity of $88.3m. It held $323m in cash against $188m of debt: net cash of $135m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents201386315323314
Receivables3895142224343
Inventory415162843
Total current assets246504485589725
Goodwill1012121212
Total assets331588568690827
Accounts payable3941726696
Total current liabilities97139230379510
Short-term debt——07070
Long-term debt94178181118118
Total debt95180181188188
Total liabilities222397511602721
Shareholders' equity1101915788105
Net debt (negative = net cash)−106−206−135−135−126
Shares outstanding43m47m49m51m53m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AXSM vs SUPNAXSM vs CORTAXSM vs HRMYANIP vs AXSM

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Axsome Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Axsome Therapeutics, Inc.